Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

321. Diagnosis of osteoporosis and assessment of fracture risk. (Abstract)

Diagnosis of osteoporosis and assessment of fracture risk. The diagnosis of osteoporosis centres on the assessment of bone mineral density (BMD). Osteoporosis is defined as a BMD 2.5 SD or more below the average value for premenopausal women (T score < -2.5 SD). Severe osteoporosis denotes osteoporosis in the presence of one or more fragility fractures. The same absolute value for BMD used in women can be used in men. The recommended site for diagnosis is the proximal femur with dual energy X

2002 Lancet

322. Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis Treatment of established osteoporosis: a systematic review and cost-utility analysis Treatment of established osteoporosis: a systematic review and cost-utility analysis Kanis J A, Brazier J E, Stevenson M, Calvert N W, Lloyd Jones M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Kanis J A, Brazier J E, Stevenson M, Calvert N W, Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 2002; 6(29): 1-146 Authors' objectives A variety of agents are available for the treatment of osteoporosis. This review examines the evidence for their efficacy, and their cost-effectiveness is modelled. Authors' conclusions Cost-effective scenarios for several interventions in the management

2002 Health Technology Assessment (HTA) Database.

323. Screening for postmenopausal osteoporosis

Screening for postmenopausal osteoporosis Screening for postmenopausal osteoporosis Screening for postmenopausal osteoporosis Nelson H D, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson H D, Helfand M. Screening for postmenopausal osteoporosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive (...) Services Task Force Systematic Evidence Review No. 17. 2002 Authors' objectives To examine evidence on the benefits and harms of screening asymptomatic postmenopausal women for osteoporosis. Authors' conclusions Although there is no direct evidence that screening prevents fractures, there is evidence that the prevalences of osteoporosis and fractures increase with age, that the short-term risk of fracture can be estimated by bone measurement tests and risk factor assessment, and that treatment may

2002 Health Technology Assessment (HTA) Database.

324. Hormone replacement therapy and osteoporosis

Hormone replacement therapy and osteoporosis Hormone replacement therapy and osteoporosis Hormone replacement therapy and osteoporosis Nelson H D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson H D. Hormone replacement therapy and osteoporosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task (...) cohort studies. Trials indicate that raloxifene increases bone density and protects against vertebral fractures. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Bone Density; Hormone Replacement Therapy; Osteoporosis, Postmenopausal; Postmenopause; Women Language Published English Country of organisation United States Address for correspondence Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax

2002 Health Technology Assessment (HTA) Database.

325. Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis

Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 17(5). 2002 Authors' objectives The objective of this Assessment

2002 Health Technology Assessment (HTA) Database.

326. Osteoporosis in postmenopausal women: diagnosis and monitoring

Osteoporosis in postmenopausal women: diagnosis and monitoring Osteoporosis in postmenopausal women: diagnosis and monitoring Osteoporosis in postmenopausal women: diagnosis and monitoring Nelson H D, Morris C D, Kraemer D F, Mahon S, Carney N, Nygren P M, Helfand M Authors' objectives To assess the effectiveness of various strategies for diagnosing and monitoring postmenopausal women with osteoporosis. The review aimed to address the following six specific questions. 1. What is the role (...) with osteoporosis for secondary causes? 6. What are the costs and cost-effectiveness of various diagnostic strategies? (Not addressed in this abstract.) Searching MEDLINE (1966 to 2000) and HealthSTAR (1975 to 2000) were searched for relevant articles; the search strategies were presented in full in an appendix to the report. Additional studies were sought by checking the reference lists of systematic reviews, and by contacting experts in the field and the manufacturers of bone density measurement tests. All

2002 DARE.

327. Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis Treatment of established osteoporosis: a systematic review and cost-utility analysis Treatment of established osteoporosis: a systematic review and cost-utility analysis Kanis J A, Brazier J E, Stevenson M, Calvert N W, Lloyd Jones M Authors' objectives To compare the effectiveness of pharmacological and non-pharmacological interventions in preventing osteoporotic fractures in patients with osteopaenia (...) , osteoporosis or established osteoporosis. Searching A number of databases including MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched; further details were reported in the review. Full search strategies were also reported to be available from the authors on request. There were no language restrictions. In addition, the references lists of relevant studies were checked and citations searches were carried out using the Science Citation Index. Further attempts to identify studies were

2002 DARE.

328. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment

Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians Authors' objectives To study the effectiveness of treatments for glucocorticoid-induced osteoporosis on bone mineral density (BMD) or fractures. Searching The authors (...) , calcitonin, calcium, vitamin D and vitamin D metabolites, fluoride, hormone replacement therapy, parathyroid hormone, deflazacort and budesonide. Participants included in the review Participants with glucocorticoid-induced osteoporosis or who were taking oral glucocorticoids were included in the review. Outcomes assessed in the review To be included in the review, the studies had to present replicated BMD measurements or fractures as outcome measures. The outcome measurements included BMD at the lumbar

2002 DARE.

329. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women

Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women Nagata-Kobayashi S, Shimbo T, Fukui T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four main strategies to determine the cost-effectiveness (CE) of screening for osteoporosis in Japanese women were compared. Dual energy X-ray absorptiometry (DXA) of the femoral neck was selected as the screening method. The following strategies were compared: no intervention, hormone replacement therapy (HRT) for patients with a diagnosis of osteoporosis, HRT for patients

2002 NHS Economic Evaluation Database.

330. The cost utility of bisphosphonate treatment in established osteoporosis

The cost utility of bisphosphonate treatment in established osteoporosis The cost utility of bisphosphonate treatment in established osteoporosis The cost utility of bisphosphonate treatment in established osteoporosis Iglesias C P, Torgerson D J, Bearne A, Bose U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of risendronate, a new bisphosphonate treatment, for the prevention of vertebral and non-vertebral fractures among women with severe osteoporosis. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised women with severe osteoporosis, which was defined as pre-existing fragility fracture and low bone mineral density. A hypothetical

2002 NHS Economic Evaluation Database.

331. Intervention thresholds for osteoporosis

Intervention thresholds for osteoporosis Intervention thresholds for osteoporosis Intervention thresholds for osteoporosis Kanis J A, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology The health interventions examined in the study were several treatments for the prevention of hip fracture in women at different levels of risk for osteoporosis. The interventions, such as vitamin D with calcium, bisphosphonate or hormone replacement therapies, were not explicitly compared, but a range of efficacy levels, which the authors stated reflected the efficacy of these treatments, was considered. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study

2002 NHS Economic Evaluation Database.

332. Guidelines for the treatment of postmenopausal osteoporosis for general practitioners

Guidelines for the treatment of postmenopausal osteoporosis for general practitioners Sheila O’Neill, MB, BCh, BAO, MICGP, is Clinical Director, Betty Byrne Henderson Centre, Royal Women’s Hospital, Queensland. Philip Sambrook, (Chairperson), LLB, MD, FRACP, is Professor of Rheumatology, Royal North Shore Hospital, New South Wales. Terry Diamond, MB, BCh, MRCP, FRACP, is Associate Professor of Endocrinology, St George Hospital, New South Wales. Peter Ebeling, MD, FRACP, is Associate Professor (...) , Final year MBBS student, is Research Assistant, University of Queensland. Caryl Nowson, PhD BSc, is Senior Lecturer, School of Health Sciences, Deakin University, Victoria. Nick Pocock, MDBS, FRACP, is Associate Professor of Medicine, Department of Nuclear Medicine, St Vincents Hospital, New South Wales. Margaret Williamson, MBChB, MRCP, FRACP, is Visiting Endocrinologist, Princess Alexandra Hospital, Queensland. BACKGROUND Osteoporosis Australia has been committed to the education of general

2002 The Royal Australian College of General Practitioners

333. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. (Abstract)

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. Large segments of the population at risk for osteoporosis and fracture have not been evaluated, and the usefulness of peripheral measurements for short-term prediction of fracture risk is uncertain.To describe the occurrence of low bone mineral density (BMD) in postmenopausal women, its risk factors, and fracture incidence during short (...) -term follow-up.The National Osteoporosis Risk Assessment, a longitudinal observational study initiated September 1997 to March 1999, with approximately 12 months of subsequent follow-up.A total of 200 160 ambulatory postmenopausal women aged 50 years or older with no previous osteoporosis diagnosis, derived from 4236 primary care practices in 34 states.Baseline BMD T scores, obtained from peripheral bone densitometry performed at the heel, finger, or forearm; risk factors for low BMD, derived from

2001 JAMA

334. Bisphosphonates for osteoporosis in people with cystic fibrosis. (Abstract)

Bisphosphonates for osteoporosis in people with cystic fibrosis. Osteoporosis is a disorder of bone mineralization that can lead to reduced bone mineral density and an increased risk for fractures. It is found in about one third of adults with cystic fibrosis. Bisphosphonates have been shown to increase bone mineral density and decrease the risk of new fractures in post-menopausal women and in patients receiving long-term oral corticosteroids.To assess the effects of bisphosphonates (...) books for osteoporosis conferences were hand-searched by the authors. The most recent search(es) were conducted in February 2001.Randomised controlled trials of at least six months duration that studied the use of bisphosphonates in adults with cystic fibrosis were considered for inclusion. Outcomes included one of the following: fractures, bone mineral density, quality of life, adverse events, study withdrawals, or survival.Information on study design, participants, interventions, and outcomes

2001 Cochrane

335. Etidronate for treating and preventing postmenopausal osteoporosis. (Abstract)

Etidronate for treating and preventing postmenopausal osteoporosis. To systematically review the efficacy of etidronate on bone density, fractures and toxicity in postmenopausal women.We searched MEDLINE from 1966 to December 1998, examined citations of relevant articles, and the proceedings of international osteoporosis meetings. We contacted osteoporosis investigators to identify additional studies, primary authors, and pharmaceutical industry sources for unpublished data.We included thirteen

2001 Cochrane

336. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. (Abstract)

Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. Data on the efficacy and safety of ipriflavone for prevention of postmenopausal bone loss are conflicting.To investigate the effect of oral ipriflavone on prevention of postmenopausal bone loss and to assess the safety profile of long-term treatment with ipriflavone in postmenopausal osteoporotic women.Prospective, randomized, double-blind, placebo-controlled, 4-year study conducted in 4 centers

2001 JAMA Controlled trial quality: predicted high

337. Osteoporosis and fractures among people aged 65 and over: recommendations for an integrated framework for action in Quebec

Osteoporosis and fractures among people aged 65 and over: recommendations for an integrated framework for action in Quebec Osteoporosis and fractures among people aged 65 and over: recommendations for an integrated framework for action in Quebec Osteoporosis and fractures among people aged 65 and over: recommendations for an integrated framework for action in Quebec Rossignol M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Rossignol M. Osteoporosis and fractures among people aged 65 and over: recommendations for an integrated framework for action in Quebec. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 01-4 RE. 2001 Authors' objectives The objective of this study is to summarize the various reports published worldwide on osteoporosis screening, in order to 1) describe

2001 Health Technology Assessment (HTA) Database.

338. Osteoporosis in postmenopausal women: diagnosis and monitoring

Osteoporosis in postmenopausal women: diagnosis and monitoring Osteoporosis in postmenopausal women: diagnosis and monitoring Osteoporosis in postmenopausal women: diagnosis and monitoring Agency for Healthcare Research and Quality Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Agency for Healthcare Research and Quality. Osteoporosis (...) in postmenopausal women: diagnosis and monitoring. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 28. 2001 Authors' objectives This report examines the evidence on the effectiveness of various strategies for diagnosing and monitoring postmenopausal women with osteoporosis. Specifically, it addresses: (1) the role of risk factors in identifying high-risk women and guiding their initial treatment, (2) the advantages and disadvantages of various techniques

2001 Health Technology Assessment (HTA) Database.

339. Biochemical markers for bone turnover in osteoporosis

Biochemical markers for bone turnover in osteoporosis Biochemical markers for bone turnover in osteoporosis Biochemical markers for bone turnover in osteoporosis Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Biochemical markers for bone turnover in osteoporosis. Bloomington (...) MN: Institute for Clinical Systems Improvement (ICSI) 2001 Authors' objectives This review aims to assess the available evidence on the use of biochemical markers for bone turnover measurement in osteoporosis. Authors' conclusions With regard to the use of biochemical markers of bone turnover in osteoporosis, the ICSI Technology Assessment Committee finds the following: The assessment of serum and urine biochemical markers of bone turnover is safe and minimally invasive. While there is some

2001 Health Technology Assessment (HTA) Database.

340. Teriparatide for osteoporosis - horizon scanning review

Teriparatide for osteoporosis - horizon scanning review Teriparatide for osteoporosis - horizon scanning review Teriparatide for osteoporosis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Teriparatide for osteoporosis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New (...) and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on teriparatide (Forteo) for osteoporosis. Authors' conclusions - Clinical impact: Teriparatide is the first of a new class of drug for the management of osteoporosis-related fractures and because of the size of the patient group may lead to a significant clinical impact. - Service impact: The introduction of teriparatide for osteoporosis is unlikely to cause a significant service impact. Although

2001 Health Technology Assessment (HTA) Database.